diabetic retinopathy, and wet AMD, benefiting patients unresponsive to current treatments. The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via ...

Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...

Patients with a foveal bulge had significantly enhanced visual acuity if they also had resolved diabetic macular edema (DME) ...

OCT angiography can measure changes in the foveal avascular zone (FAZ) area. FAZ area deteriorated in stable eyes with proliferative diabetic retinopathy and macular capillary nonperfusion.

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Treatment of hypertensive retinopathy begins with controlling hypertension. Some of the complications can be treated by an ophthalmologist with injectable medications into the eye as well as laser ...

311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular's second registrational trial of AXPAXLI in wet AMD, as of January 10, 2024 First wet AMD registrational trial ...

“OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degenerati ... leaders MALVERN, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME, ...

Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their ...